EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline

EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications has closed an oversubscribed USD $21.5 million (UK £15.5m) Series A financing round. The proceeds will be used to further advance the company’s microbiome drug pipeline and underpin its product development and manufacturing capabilities. The company was founded by EBS alumni Dr James McIlroy after recognising the therapeutic potential of the microbiome with the vision of building one of world’s leading microbiome drug development companies. 

Related posts

Supplant announces $24m investment

We’re delighted to learn that EBS alumni Dr Tom Simmons and his company Supplant Inc., have just closed a series-A venture capital financing round to commercialise their low-cost sugar replacement made from plant fibre. The company, started in 2017 after […]